Opendata, web and dolomites

REVERT SIGNED

taRgeted thErapy for adVanced colorEctal canceR paTients

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "REVERT" data sheet

The following table provides information about the project.

Coordinator
SAN RAFFAELE ROMA SRL 

Organization address
address: VIA DELLA PISANA 235
city: ROMA RM
postcode: 163
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 5˙887˙273 €
 EC max contribution 5˙887˙273 € (100%)
 Programme 1. H2020-EU.3.1.1. (Understanding health, wellbeing and disease)
 Code Call H2020-SC1-2019-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2023-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SAN RAFFAELE ROMA SRL IT (ROMA RM) coordinator 998˙125.00
2    UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA IT (ROMA) participant 1˙545˙312.00
3    GENXPRO GMBH DE (FRANKFURT) participant 443˙750.00
4    MALMO UNIVERSITET SE (MALMOE) participant 399˙420.00
5    SERVICIO MURCIANO DE SALUD ES (MURCIA) participant 343˙250.00
6    UMEA UNIVERSITET SE (UMEA) participant 325˙750.00
7    CLUSTERUL REGIONAL INOVATIV DE IMAGISTICA MOLECULARA SI STRUCTURALA NORD-EST (IMAGO-MOL) RO (IASI) participant 299˙000.00
8    FUNDACION UNIVERSITARIA SAN ANTONIO ES (MURCIA) participant 298˙250.00
9    OLOMEDIA SRL IT (PALERMO) participant 248˙687.00
10    BIOVARIANCE GMBH DE (WALDSASSEN) participant 248˙500.00
11    INSTITUTUL REGIONAL DE ONCOLOGIE IASI RO (IASI) participant 237˙187.00
12    AZIENDA ULSS 4 VENETO ORIENTALE IT (SAN DONA DI PIAVE) participant 200˙541.00
13    BUNDESANSTALT FUER MATERIALFORSCHUNG UND -PRUEFUNG DE (BERLIN) participant 150˙000.00
14    LUXEMBOURG INSTITUTE OF HEALTH LU (LUXEMBOURG) participant 149˙500.00

Map

 Project objective

The REVERT project will address the specific challenge of understanding at system level the pathophysiology of mCRC cancer in patients responding well or poorly to therapies, in order to design optimal strategy for mCRC on a case by case basis, with therapeutic interventions modulated depending on patient’s features. Accordingly, REVERT will build up an innovative artificial intelligence (AI)-based decision support system using the experience and the real-world data of several general Hospitals operating in the EU healthcare system ultimately aimed at developing an improved and innovative model of combinatorial therapy - based on a personalised medicine approach - that identifies the most efficient and cost-effective therapeutic intervention for patients with unresectable mCRC. This goal will be pursued through the building of the REVERT-DataBase (RDB) thanks to a large number of standardized biobank samples with related structured data, and clinical databases (including known clinical and biological features as well as new, potential prognostic/predictive biomarkers) from several major clinical European centres. The RDB, in turn, will be used to build a sophisticated computational framework based on AI to evaluate its impact on survival and quality of life in a prospective clinical trial through testing of new treatment sequences of the available and authorised molecular targeted drugs in patients with mCRC. In the end, the REVERT will also generate an EU- network among SMEs, Research Institutions, Clinical Centres and Biobanks focused on R&D in the field of AI-Health for the development of personalised medicine. The REVERT software system will ensure the integrity of data and privacy management in respect to national rules, the EU's GDPR (Reg. EU 2016/679) and the EU Charter of Fundamental Rights. The RDB and AI services will be open to all partners during and after project’s completion, available also to EU research Institutions for future studies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "REVERT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "REVERT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.1.)

ATHENA (2019)

Assays for the identification of Thyroid Hormone axis-disrupting chemicals: Elaborating Novel Assessment strategies

Read More  

ERGO (2019)

Breaking down the wall between human health and environmental testing of endocrine disrupters: EndocRine Guideline Optimisation

Read More  

GO-DS21 (2020)

Gene overdosage and comorbidities during the early lifetime in Down Syndrome

Read More  
lastchecktime (2020-07-14 21:39:17) correctly updated